AVBCC Value-Based Voices

In this episode of Value-Based Voices, we delve into the mission and inner workings of the NCCN, a cornerstone organization shaping cancer treatment standards in the U.S. and beyond. We're joined by Bill McGivney, PhD , Principal, McGivney Global Advisors, and Former CEO, NCCN; and host Nicolas Ferreyros , Managing Director, Policy, Advocacy, and Communications, Community Oncology Alliance. ...

We're taking a deep dive into the upcoming Global Cancer Research and Innovation Symposium (GCRIS) in this latest episode of Value-Based Voices. Join GCRIS Scientific Co-chairs Stan Skrzypczak, MS, MBA , Managing Partner, 5 Prime Life Science Consulting, and Nick Sarlis, MD, PhD, FACP , Chief Medical Officer, Cleara Biotech, as they talk with GCRIS Co-chair Matt Vossler , Managing Director, D...

Most cancer drugs today are more effective and accessible than ever—yet patients often face crushing costs because our healthcare system still values profit over patient benefit. What if the key to transforming cancer care affordability lies in rethinking insurance design, reforming PBMs, and empowering employers with transparent data?  In this eye-opening episode of Value-Based Voices, host Jayso...

Most treatments and diagnostics once took years and hundreds of millions of dollars. Today, it costs less than $100,000 to sequence a genome and open the door to tailored cancer therapies that could save lives. But understanding tumor biology is only half the battle. The real challenge lies in interpreting complex genetic data quickly, accurately, and at scale. In this episode of AVBCC’s Value-Bas...

International reference pricing could drastically reshape drug costs in the U.S. and threaten domestic innovation. In this latest episode of AVBCC’s Value-Based Voices, join Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Inc., and Member of the AVBCC Board of Directors, and healthcare policy strategist Brian Reid, MS, Founder of Reid Strategic, as they unpack the complex debate over t...

Most companies, and even policymakers, are betting big on importing international drug prices — but what does that really mean for cancer care in America?  In this episode of Value-Based Voices , Jayson Slotnik, JD, MPH,  Partner, Health Policy Strategies, Inc., dives into the evolving landscape of drug pricing reforms, unlocking why policies like the Most Favored Nation (MFN) and the Global Bench...

There are countless opportunities hidden in the data-driven tasks pharmacists do every day, and AI is ready to unlock them. But what happens when automation dramatically increases productivity in pharmacy, and how do regulations, workforce, and patient care evolve in tandem? In this latest episode of AVBCC's Value-Based Voices, join Ira Klein , MD, MBA, FACP, VP Medical Affairs, Payer Relatio...

Is consolidation in cancer care truly the best path forward, or does independence offer greater benefits? In this episode of Value-Based Voices Sarah Alwardt , PhD, President, Avalere Health, and Jeff Patton, MD , CEO, OneOncology, discuss the nuances of consolidation versus independence in cancer care, the impact of policy and capital access, and the future of value-based oncology. Gain insights...

Commercial health plans may have been missing from J.P. Morgan 2026, but government had a big presence! Value-Based Voices host Burt Zweigenhaft, PhD, and nationally recognized health policy expert Liz Fowler, PhD, JD, share their observations from this year’s meeting and key insights around most-favored nation prescription drug pricing, 340B, PBMs, Medicare site neutrality, AI, and of course valu...

Where was the drama at JP Morgan this year? Host Burt Zweigenhaft, PhD, and seasoned healthcare executive Jeff Berkowitz, JD, debate why the 2026 meeting seemed to be missing its normal electricity. They also share their thoughts around challenges with direct-to-patient models, most-favored-nation and its impact on product launch and pricing both in the US and Europe, and how AI may or may not be...